At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMND Clearmind Medicine, Inc.
Market Closed 05-15 16:00:00 EDT
0.5200
-0.0086
-1.63%
盘后0.5201
+0.0001+0.02%
19:57 EDT
High0.5379Low0.5200Vol264.96K
Open0.5245D1 Closing0.5286Amplitude3.39%
Mkt Cap5.30MTradable Cap5.27MTotal Shares10.19M
T/O139.85KT/O Rate2.61%Tradable Shares10.14M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Clearmind Medicine CEO DR. Adi Zuloff-Shani Named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.c.
THOMSON REUTERS  ·  05-15 20:35
Clearmind Medicine CEO DR. Adi Zuloff-Shani Named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.c.
Clearmind doses 2 more patients in CMND-100 alcohol use disorder trial cohort 4
Reuters  ·  05-12
Clearmind doses 2 more patients in CMND-100 alcohol use disorder trial cohort 4
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants NOW Treated in Ongoing Phase I/Iia Trial of Cmnd-100 for Alcohol Use Disorder
THOMSON REUTERS  ·  05-12
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants NOW Treated in Ongoing Phase I/Iia Trial of Cmnd-100 for Alcohol Use Disorder
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
GlobeNewswire  ·  05-12
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
Clearmind Medicine to host “Inside MEAI” webinar on CMND-100 trial data
Reuters  ·  05-11
Clearmind Medicine to host “Inside MEAI” webinar on CMND-100 trial data
Clearmind Medicine Announces “Inside Meai” Webinar Featuring New Insights From Cmnd-100 Psychedelic Clinical Trial
THOMSON REUTERS  ·  05-11
Clearmind Medicine Announces “Inside Meai” Webinar Featuring New Insights From Cmnd-100 Psychedelic Clinical Trial
BRIEF-Clearmind Medicine Announces Filing Of European Patent Application For Novel Psychedelic Compounds For The Treatment Of Ptsd
Reuters  ·  05-05
BRIEF-Clearmind Medicine Announces Filing Of European Patent Application For Novel Psychedelic Compounds For The Treatment Of Ptsd
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of Ptsd
THOMSON REUTERS  ·  05-05
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of Ptsd
Clearmind names Hila Kiron-Revach board chair after Amitay Weiss steps down
Reuters  ·  05-01
Clearmind names Hila Kiron-Revach board chair after Amitay Weiss steps down
Clearmind evaluates MEAI for FDA breakthrough therapy designation in alcohol use disorder trial
Reuters  ·  04-27
Clearmind evaluates MEAI for FDA breakthrough therapy designation in alcohol use disorder trial
Clearmind Medicine Inc - Has Not Submitted or Received FDA Breakthrough Therapy Designation for Meai
THOMSON REUTERS  ·  04-27
Clearmind Medicine Inc - Has Not Submitted or Received FDA Breakthrough Therapy Designation for Meai
Clearmind Medicine issues $2.7 million convertible notes at 10% discount
Reuters  ·  04-21
Clearmind Medicine issues $2.7 million convertible notes at 10% discount
Clearmind welcomes Trump executive order speeding FDA review of breakthrough psychedelic therapies
Reuters  ·  04-21
Clearmind welcomes Trump executive order speeding FDA review of breakthrough psychedelic therapies
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
Reuters  ·  04-20
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
Clearmind says CMND-100 meets primary safety endpoint in AUD Phase I/IIa trial
Reuters  ·  04-20
Clearmind says CMND-100 meets primary safety endpoint in AUD Phase I/IIa trial
Clearmind Medicine Inc - Cmnd-100 Shows High Safety Profile at Highest Dosage With No Serious Adverse Events
THOMSON REUTERS  ·  04-20
Clearmind Medicine Inc - Cmnd-100 Shows High Safety Profile at Highest Dosage With No Serious Adverse Events
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
GlobeNewswire  ·  04-20
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
TIPRANKS  ·  04-16
Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
Clearmind announces DSMB recommendation to continue CMND-100 trial
TIPRANKS  ·  04-16
Clearmind announces DSMB recommendation to continue CMND-100 trial
Clearmind advances CMND-100 alcohol use disorder trial, raises dose to 160 mg
Reuters  ·  04-15
Clearmind advances CMND-100 alcohol use disorder trial, raises dose to 160 mg

Introduction

Company Name.
Clearmind Medicine, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Issue price:
--